Health ❯ Public Health ❯ HIV/AIDS ❯ Prevention

Lenacapavir

Southern Africa Begins Rollout of Twice-Yearly HIV Prevention Shot Lenacapavir

Experts warn current commitments fall far short of demand.

World AIDS Day Sounds Alarm as Funding Cuts Undermine Global HIV Response

Gilead Starts Shipping Twice-Yearly HIV Prevention Shot to Eswatini and Zambia

First Lenacapavir Shipments Reach Zambia and Eswatini as U.S. Excludes South Africa From Donated Doses

South Africa Approves Twice-Yearly HIV Prevention Shot, Clearing Path to 2026 Rollout

NHS to Roll Out First Long‑Acting HIV Prevention Injection After NICE Green Light

South Africa Sets April 2026 Rollout for Twice-Yearly HIV-Prevention Shot, With Limited Early Supply

Deals Set $40 Generics of Twice-Yearly HIV Prevention Shot for 120 Countries by 2027

U.S. to Buy Lenacapavir PrEP Doses to Reach Up to 2 Million People by 2028

EU Backs First Twice-Yearly Injectable for HIV Prevention

State Department Proposes Major Cut to PEPFAR Despite Congressional Reprieve

WHO Endorses Twice-Yearly Lenacapavir Injections for HIV Prevention

UN Warns US Aid Suspension Risks Reversing Global HIV Progress

FDA Approves Six-Month HIV Prevention Injection Lenacapavir

FDA Approves Yeztugo, Twice-Yearly HIV Prevention Injection

FDA Approves Twice-Yearly Lenacapavir Injection for HIV Prevention

Lenacapavir Injection Shows 96% Efficacy in Preventing HIV